BOC-D-4-氟苯丙氨酸 | 57292-45-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-D-4-氟苯丙氨酸
• 中文别名: 丁氧羰基对氟-D-苯丙氨酸；N-叔丁氧羰基-D-4-氟苯丙氨酸；N-(叔丁氧羰基)-4-氟-D-苯丙氨酸；Boc-D-4-氟苯丙氨酸
• 英文名称: (R)-N-(tert-butoxycarbonyl)-4-fluorophenylalanine
• 英文别名: N-(tert-butoxycarbonyl)-4-fluoro-D-phenylalanine；Boc-4-fluoro-D-phenylalanine；(2R)-3-(4-fluorophenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
• CAS: 57292-45-2
• 化学式: C₁₄H₁₈FNO₄
• 分子量: 283.3
• InChiKey: RCXSXRAUMLKRRL-LLVKDONJSA-N

物化性质

• 稳定性/保质期：

  如果按照规格正确使用和储存，则不会分解，未发现有已知的危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  BOC-D-4-氟苯丙氨酸 在 palladium on activated charcoal 氢气 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 (R)-2-[(R)-2-(4-tert-Butylcarbamoyl-4-cyclohexyl-piperidin-1-yl)-1-(4-fluoro-benzyl)-2-oxo-ethylcarbamoyl]-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of (2S)-N-[(1R)-2-[4-cyclohexyl-4-[[(1,1-dimethylethyl)amino]carbonyl]-1-piperidinyl]-1-[(4-fluorophenyl)methyl]-2-oxoethyl]-4-methyl-2-piperazinecarboxamide (MB243), a potent and selective melanocortin subtype-4 receptor agonist

  摘要：

  We report the discovery and optimization of substituted 2-piperazinecarboxamides as potent and selective agonists of the melanocortin subtype-4 receptor. Further in vivo development of lead agonist, MB243, is disclosed. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.10.020
• 作为产物：
  描述：

  methyl (R)-2-tert-butoxycarbonylamino-3-(4-fluorophenyl)propanoate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 6.0h， 生成 BOC-D-4-氟苯丙氨酸
  参考文献：
  名称：

  Discovery of pyrrolopyrimidine inhibitors of Akt

  摘要：

  The discovery and optimization of a series of pyrrolopyrimidine based protein kinase B (Pkb/Akt) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent inhibition of all three Akt isoforms and knockdown of phospho-PRAS40 levels in LNCaP cells and tumor xenografts. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.053

文献信息

• Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith
  申请人：D'Sidocky Neil R.

  公开号：US20080242694A1

  公开（公告）日：2008-10-02

  Provided herein are Heterocyclic Compounds having the following structure: wherein R 1 , R 2 , X, Y and Z are as defined herein, compositions comprising an effective amount of a Heterocyclic Compound and methods for treating or preventing cancer, inflammatory conditions, immunological conditions, metabolic conditions and conditions treatable or preventable by inhibition of a kinase pathway comprising administering an effective amount of a Heterocyclic Compound to a patient in need thereof.

  本文提供具有以下结构的杂环化合物： 其中R1、R2、X、Y和Z如本文所定义，包含有效量杂环化合物的组合物，以及治疗或预防癌症、炎症性疾病、免疫疾病、代谢性疾病以及通过给予患者需要的有效量杂环化合物来抑制激酶途径治疗或预防的疾病的方法。
• Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as
  申请人：Pfizer, Inc.

  公开号：US06107329A1

  公开（公告）日：2000-08-22

  Compounds of Formula (1) wherein R.sub.6 is carboxy, (C.sub.1 -C.sub.8)alkoxycarbonyl, benzyloxycarbonyl, C(O)NR.sub.8 R.sub.9 or C(O)R.sub.12 as glucogen phosphorylase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat diabetes, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis and myocardial ischemia in mammals.

  公式（1）的化合物，其中R6是羧基，（C1-C8）烷氧基羰基，苄氧基羰基，C(O)NR8R9或C(O)R12作为葡萄糖磷酸化酶抑制剂，包含此类抑制剂的药物组合物以及使用此类抑制剂治疗哺乳动物中的糖尿病、高血糖、高胆固醇血症、高血压、高胰岛素血症、高脂血症、动脉粥样硬化和心肌缺血。
• Fused purine derivatives
  申请人：——

  公开号：US20030176698A1

  公开（公告）日：2003-09-18

  A condensed purine derivative represented by Formula (I): 1 wherein X—Y—Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V 1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V 2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V 1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R 1a N—C═O and R 2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR 7 R 8 , —CO 2 H, a lower alkoxycarbonyl group, —COHal, —CONR 9 R 10 or —CHO, V 2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  一个由公式(I)表示的浓缩嘌呤衍生物：1 其中，X—Y—Z代表R1N—C═O或N═C—W，R2代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团、取代或未取代的芳香杂环团、取代或未取代的脂肪杂环团等，n代表从0到3的整数，V1代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团或取代或未取代的芳香杂环团，V2代表取代的低级烷基团或取代或未取代的芳香杂环团，并且当V1代表氢原子、低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团时，例如，X—Y—Z代表R1aN—C═O并且R2代表取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的脂肪杂环团、卤素原子、低级烷基亚硫酰基团、—NR7R8、—CO2H、低级烷氧羰基团、—COHal、—CONR9R10或—CHO，V2可以代表低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团；或其药理可接受的盐。
• SUBSTITUTED PIPERIDINES AS MELANOCORTIN RECEPTOR AGONISTS
  申请人：——

  公开号：US20030236262A1

  公开（公告）日：2003-12-25

  Certain novel 4-substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction.

  某些新型的4-取代哌啶化合物是人类黑色素皮质素受体的激动剂，特别是人类黑色素皮质素-4受体（MC-4R）的选择性激动剂。因此，它们对于治疗、控制或预防对MC-4R激活敏感的疾病和疾病具有用处，如肥胖症、糖尿病、性功能障碍，包括勃起功能障碍和女性性功能障碍。
• Synthetic Analogues of Aminoadamantane as Influenza Viral Inhibitors—In Vitro, In Silico and QSAR Studies
  作者：Radoslav Chayrov、Nikolaos A. Parisis、Maria V. Chatziathanasiadou、Eleni Vrontaki、Kalliopi Moschovou、Georgia Melagraki、Hristina Sbirkova-Dimitrova、Boris Shivachev、Michaela Schmidtke、Yavor Mitrev、Martin Sticha、Thomas Mavromoustakos、Andreas G. Tzakos、Ivanka Stankova

  DOI：10.3390/molecules25173989

  日期：——

  amino acid analogues of amantadine (Amt) and rimantadine (Rim) were synthesized and their antiviral activity was evaluated against influenza virus A (H3N2). Among these analogues, the conjugation of rimantadine with glycine illustrated high antiviral activity combined with low cytotoxicity. Moreover, this compound presented a profoundly high stability after in vitro incubation in human plasma for 24 h

  合成了一系列的金刚烷胺 (Amt) 和金刚乙胺 (Rim) 的 19 种氨基酸类似物，并评估了它们对甲型流感病毒 (H3N2) 的抗病毒活性。在这些类似物中，金刚乙胺与甘氨酸的结合表现出高抗病毒活性和低细胞毒性。此外，该化合物在人血浆中体外孵育 24 小时后表现出极高的稳定性。其热稳定性是通过差热分析和重量分析确定的。甘氨酰金刚乙胺的晶体结构表明它在正交 Pbca 空间群中结晶。建立了此类化合物的构效关系，使用 CoMFA（比较分子场分析）3D 定量结构活性关系 (3D-QSAR) 研究预测合成分子的活性。此外，还进行了分子对接研究，揭示了合成分子活性的结构要求。